Key result
Subcutaneous GP IIb/IIIa inhibitor zalunfiban offers rapid, reversible platelet inhibition for early prehospital STEMI therapy.
Why the study?
Prehospital use of intravenous GPIIb/IIIa inhibitors has been limited by logistical complexity and safety concerns, prompting evaluation of whether zalunfiban overcomes these barriers for early antiplatelet therapy in STEMI.
Does zalunfiban improve outcomes when administered early in patients with ST-segment elevation myocardial infarction?
Does zalunfiban improve outcomes when administered early in patients with ST-segment elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zalunfiban offers a novel subcutaneous approach for early, potent, and reversible platelet inhibition in STEMI, potentially overcoming the limitations of traditional intravenous GPIIb/IIIa inhibitors.
Zalunfiban is a next-generation glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor developed through a novel molecular design that enables rapid, potent, and reversible platelet inhibition following single-dose subcutaneous administration. This pharmacologic profile creates an opportunity for very early antiplatelet therapy at first medical contact in patients with ST-segment elevation myocardial infarction. Historical experience with intravenous GPIIb/IIIa inhibitors has demonstrated that clinical benefit is highly dependent on early administration; however, routine prehospital use has been limited by logistical complexity and safety concerns. Recent clinical trials suggest that zalunfiban may overcome these barriers while preserving the mechanistic advantages of upstream platelet inhibition. This review summarizes the mechanism of action, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and safety profile of zalunfiban, and discusses its potential role within contemporary ST-segment elevation myocardial infarction care pathways.
Ji et al. (2026) conducted a review in ST-segment elevation myocardial infarction. Zalunfiban was evaluated. Zalunfiban, a novel subcutaneously administered glycoprotein IIb/IIIa inhibitor, offers rapid and reversible platelet inhibition for early prehospital therapy in ST-segment elevation myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: